StreetInsider.com News Articles

Form 4 Immunome Inc. For: Jun 15 Filed by: Rosett Max

Wed, 17 Jun 2026 17:26:00 -0400

si-local-file:///var/storage/secattach/20260617/26661016.html

Form 4 Immunome Inc. For: Jun 15 Filed by: Rosett Max

Wed, 17 Jun 2026 17:26:00 -0400

si-local-file:///var/storage/secattach/20260617/26661016.html

Form 144 Immunome Inc. Filed by: Rosett Max

Mon, 15 Jun 2026 14:36:00 -0400

si-local-file:///var/storage/secattach/20260615/26646777.html

Form 144 Immunome Inc. Filed by: Rosett Max

Mon, 15 Jun 2026 14:36:00 -0400

si-local-file:///var/storage/secattach/20260615/26646777.html

Form 4 Immunome Inc. For: Jun 10 Filed by: SWAIN SANDRA M

Fri, 12 Jun 2026 17:58:00 -0400

si-local-file:///var/storage/secattach/20260612/26642344.html

Form 4 Immunome Inc. For: Jun 10 Filed by: SWAIN SANDRA M

Fri, 12 Jun 2026 17:58:00 -0400

si-local-file:///var/storage/secattach/20260612/26642344.html

Form 4 Immunome Inc. For: Jun 10 Filed by: WAGENHEIM PHILIP

Fri, 12 Jun 2026 17:56:00 -0400

si-local-file:///var/storage/secattach/20260612/26642332.html

Form 4 Immunome Inc. For: Jun 10 Filed by: WAGENHEIM PHILIP

Fri, 12 Jun 2026 17:56:00 -0400

si-local-file:///var/storage/secattach/20260612/26642332.html

Form 4 Immunome Inc. For: Jun 10 Filed by: BIENAIME JEAN JACQUES

Fri, 12 Jun 2026 17:54:00 -0400

si-local-file:///var/storage/secattach/20260612/26642323.html

Form 4 Immunome Inc. For: Jun 10 Filed by: BIENAIME JEAN JACQUES

Fri, 12 Jun 2026 17:54:00 -0400

si-local-file:///var/storage/secattach/20260612/26642323.html

Form 4 Immunome Inc. For: Jun 10 Filed by: Boylan James P

Fri, 12 Jun 2026 17:52:00 -0400

si-local-file:///var/storage/secattach/20260612/26642312.html

Form 4 Immunome Inc. For: Jun 10 Filed by: Boylan James P

Fri, 12 Jun 2026 17:52:00 -0400

si-local-file:///var/storage/secattach/20260612/26642312.html

Form 4 Immunome Inc. For: Jun 10 Filed by: Barchas Isaac

Fri, 12 Jun 2026 17:48:00 -0400

si-local-file:///var/storage/secattach/20260612/26642298.html

Form 4 Immunome Inc. For: Jun 10 Filed by: Barchas Isaac

Fri, 12 Jun 2026 17:48:00 -0400

si-local-file:///var/storage/secattach/20260612/26642298.html

Form 4 Immunome Inc. For: Jun 10 Filed by: SCHAFER CAROL

Fri, 12 Jun 2026 17:46:00 -0400

si-local-file:///var/storage/secattach/20260612/26642291.html

Form 4 Immunome Inc. For: Jun 10 Filed by: SCHAFER CAROL

Fri, 12 Jun 2026 17:46:00 -0400

si-local-file:///var/storage/secattach/20260612/26642291.html

Form 8-K Immunome Inc. For: Jun 09

Fri, 12 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260612/26640690.html

Form 8-K Immunome Inc. For: Jun 09

Fri, 12 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260612/26640690.html

Immunome doses first patient in Phase 1 trial of IM-1617 cancer drug

Thu, 11 Jun 2026 07:30:32 -0400

Immunome Inc. (NASDAQ: IMNM) announced it has dosed the first patient in a Phase 1 trial evaluating IM-1617, an antibody-drug conjugate for advanced solid tumors.

IM-1617 incorporates HC74, the company's proprietary topoisomerase I inhibitor payload, and targets an undisclosed receptor tyrosine kinase. The Phase 1 study is an open-label, multicenter dose escalation and expansion trial designed to assess safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity.

The trial will include participants with advanced solid tumors, including colorectal cancer, non-small cell lung cancer, and breast cancer. Preclinical studies showed tumor regression after a single dose of IM-1617 in various solid tumor models, according to

Immunome doses first patient in Phase 1 trial of IM-1617 cancer drug

Thu, 11 Jun 2026 07:30:32 -0400

Immunome Inc. (NASDAQ: IMNM) announced it has dosed the first patient in a Phase 1 trial evaluating IM-1617, an antibody-drug conjugate for advanced solid tumors.

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors

Thu, 11 Jun 2026 07:30:00 -0400

IM-1617 is a potential first-in-class solid tumor antibody-drug conjugate (ADC) that incorporates HC74, Immunome’s proprietary topoisomerase I (TOP1) inhibitor payload
Immunome ADC pipeline momentum anticipated to continue with investigational new drug (IND) submissions for IM-1340 and IM-1335 planned for mid- and late 2026, respectively

BOTHELL, Wash.--(BUSINESS WIRE)-- Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the first patient has been dosed in the Phase 1, first-in-human trial of IM-1617, a potential first-in-class ADC directed at an undisclosed solid tumor target and incorporating HC74,

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors

Thu, 11 Jun 2026 07:30:00 -0400

IM-1617 is a potential first-in-class solid tumor antibody-drug conjugate (ADC) that incorporates HC74, Immunome’s proprietary topoisomerase I (TOP1) inhibitor payload
Immunome ADC pipeline momentum anticipated to continue with investigational new drug (IND) submissions for IM-1340 and IM-1335 planned for mid- and late 2026, respectively

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors

Thu, 11 Jun 2026 07:30:00 -0400

IM-1617 is a potential first-in-class solid tumor antibody-drug conjugate (ADC) that incorporates HC74, Immunome’s proprietary topoisomerase I (TOP1) inhibitor payload
Immunome ADC pipeline momentum anticipated to continue with investigational new drug (IND) submissions for IM-1340 and IM-1335 planned for mid- and late 2026, respectively

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors

Thu, 11 Jun 2026 07:30:00 -0400

IM-1617 is a potential first-in-class solid tumor antibody-drug conjugate (ADC) that incorporates HC74, Immunome’s proprietary topoisomerase I (TOP1) inhibitor payload
Immunome ADC pipeline momentum anticipated to continue with investigational new drug (IND) submissions for IM-1340 and IM-1335 planned for mid- and late 2026, respectively

Form 4 Immunome Inc. For: Jun 05 Filed by: BIENAIME JEAN JACQUES

Tue, 09 Jun 2026 17:40:00 -0400

si-local-file:///var/storage/secattach/20260609/26624944.html